Mekinist for prostate cancer – pro
Metastatic castration-resistant prostate cancer (mCRPC) is incurable and progression after drugs that target the androgen receptor-signaling axis is inevitable. New drugs are being sought. Sequencing of mCRPCs has not revealed frequent recurrent gain-of-function mutations in kinases, including the MAP kinases. However, one study suggests that ERK1/2 may be a potential kinase target in mCRPCs based on the clinical proteomic and transcriptomic data.
The use of Mekinist for prostate cancer is in a clinical trial: Trametinib in Treating Patients with Progressive Metastatic Castration-Resistant Prostate Cancer, NCT02881242. This phase II trial studies how well trametinib works in treating patients with castration-resistant prostate cancer that is growing or getting worse and has spread to other parts of the body. The trial is now closed to accrual but had not been published yet. As such, the proposed treatment is E/I.
Nickols, N.G., Nazarian, R., Zhao, S.G. et al. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis 22, 531538 (2019)
Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets
J.M> Draek et al, PNAS November 18, 2013
110 (49) E4762-E4769 2013